HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IdeaSphere markets Weil

This article was originally published in The Tan Sheet

Executive Summary

IdeaSphere will "assume exclusive, worldwide licensing rights" to Weil Nutritional Supplements, the New York-based firm announced Jan. 17. The product line, which was launched in March by author Andrew Weil, MD, currently is sold through Weil's website and in specialty health stores such as Whole Foods, GNC and Vitamin Shoppe. IdeaSphere will take over retail and direct marketing of the supplement line including online sales, the company states. IdeaSphere purchased Twinlab in 2003 and most recently completed the acquisition of Metabolife's non-ephedra brands including Metabolife Ultra in November (1"The Tan Sheet" Sept. 1, 2003, p. 3 and 2"The Tan Sheet" Nov. 14, 2005, In Brief)...

You may also be interested in...



Twinlab Finds Potential Buyer In IdeaSphere: End Of Blechman Era?

The proposed acquisition of Twinlab by nutritional products seller IdeaSphere would mark the end of the Blechman family ownership of the company, in place since the company's founding 35 years ago

US Supplement Industry To Enjoy Recognition Week Under Resolution Lee, Sinema Propose In Senate

Senate recognizes “dietary supplements have become a routine part of the lives of millions of individuals in the United States” and “the contributions of the natural product industry to the workforce and economy,” says ‘‘Natural Product Industry Week’’ resolution proposed by Sens. Mike Lee and Kyrsten Sinema.

Medicare Price Negotiation: Special Treatment For ‘Novel Technologies’ On PhRMA’s Advocacy Agenda

Novartis CEO Vasant Narasimhan, PhRMA's incoming board chair, says in an interview that the brand drug association has a slate of issues to pursue as it works to shape the implementation of the Medicare price negotiation program in the name of preserving innovation.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel